Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › semaglutide

semaglutide

63 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of semaglutide

72 trials tracked of semaglutide: 54 in phase 3 or 4 and 46 with published results. The most-cited published study has 6709 citations.

72Trials tracked
54Phase 3 & 4
0Recruiting
46With published results
Phase distribution
Phase 4 6 Phase 3 48 Phase 2 16 Phase 1 1 Other / NA 1
  1. Phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Completed · 6,709 cited
  2. Phase 3 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 4,686 cited
  3. Phase 3 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity Completed · 4,608 cited
  4. Phase 3 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Completed · 1,960 cited
  5. Phase 3 Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity Completed · 1,481 cited
  6. Phase 3 STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity Completed · 1,310 cited
Show 44 more trials
  1. Phase 3 Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 1,266 cited
  2. Phase 3 Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program Completed · 1,035 cited
  3. Phase 3 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Completed · 885 cited
  4. Phase 3 Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 795 cited
  5. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 766 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Completed · 718 cited
  7. Phase 3 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity Completed · 655 cited
  8. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 585 cited
  9. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 581 cited
  10. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 478 cited
  11. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Completed · 473 cited
  12. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Completed · 451 cited
  13. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 447 cited
  14. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Completed · 447 cited
  15. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 410 cited
  16. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 402 cited
  17. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Completed · 397 cited
  18. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Completed · 369 cited
  19. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed · 342 cited
  20. Phase 3 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes Completed · 327 cited
  21. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 293 cited
  22. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed · 283 cited
  23. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 275 cited
  24. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 224 cited
  25. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 210 cited
  26. Phase 3 A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes Completed · 176 cited
  27. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Completed · 126 cited
  28. Phase 3 A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes Completed · 125 cited
  29. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Completed · 123 cited
  30. Phase 3 Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. Completed · 118 cited
  31. Phase 3 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes Completed · 80 cited
  32. Phase 3 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range Completed · 75 cited
  33. Phase 3 A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) Completed · 64 cited
  34. Phase 3 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight Completed · 29 cited
  35. Phase 3 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes Completed · 18 cited
  36. Phase 4 Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial Completed · 15 cited
  37. Phase 3 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) Completed · 13 cited
  38. Phase 3 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Completed · 8 cited
  39. Phase 4 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Completed · 5 cited
  40. Phase 4 Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D Completed · 5 cited
  41. Phase 4 Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes Completed
  42. Phase 4 Impact of Semaglutide on CD34+ EPC and Fat Derived MSC Completed
  43. Phase 4 A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Completed
  44. Phase 3 Semaglutide in CFRD Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GLP-1RA use associated with lower obesity-related cancer risk in meta-analysis of adults with T2DM/obesity
Diabetes & Endocrinology Meta-analysis
GLP-1RA use associated with lower obesity-related cancer risk in meta-analysis of adults with T2DM/obesity Large review finds link between GLP-1 drugs and lower obesity-related cancer risk
A systematic review and meta-analysis of 3,960,974 adults with type 2 diabetes and/or obesity found GLP-1RA use was associated with a signif…
A large review of studies involving nearly 4 million adults with type 2 diabetes or obesity found that using GLP-1 receptor agonists was ass…
Apr 2, 2026
Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease
Diabetes & Endocrinology Cohort
Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease Can a diabetes drug help people with kidney failure? A small study looks for clues
A retrospective cohort study of 17 adults with T2DM and ESRD (including those on hemodialysis) found descriptive reductions in HbA1c (-0.31%…
A small study found that injectable semaglutide helped adults with kidney failure lose an average of 12.6 kilograms while reducing insulin n…
Frontiers Apr 1, 2026
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults
Pulmonology & Critical Care FDA Approval
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults FDA approves a new treatment for a serious lung condition called pulmonary arterial hypertension
The FDA has approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capac…
A new FDA-approved injection helps adults with pulmonary arterial hypertension exercise longer, improve daily life, and lower the risk of ho…
FDA Mar 31, 2026